Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL).
Systemic aldosterone plays an important role in the development of the microvascular disease and glomerular damage of the kidney in patients with diabetes mellitus and hyperlipidemia. Here, we investigated the possibility of local production of aldosterone in the kidney, using human primary glomerular mesangial cells. These cells produced both pregnenolone and aldosterone measured by specific radioimmunoassay and/or gas chromatography/mass spectrometry (GC/MS) methods. The production of both steroids was significantly stimulated by treatment with LDL, while angiotensin II had a synergistic effect. Adrenocorticotropic hormone (ACTH) and (Bu)2cAMP, on the other hand, failed to stimulate aldosterone production by these cells, suggesting that the local production of this steroid by mesangial cells is regulated differently from that of adrenal zona glomerulosa cells. Mesangial cells expressed the mRNA of the LDL receptor and steroidogenic enzymes, such as P450scc, 3beta-hydroxysteroid dehydrogenase (3beta-HSD), 21-hydroxylase and CYP11B2. Mesangial cells also expressed mRNA of the mineralocorticoid receptor (MR), and LDL stimulated its abundance by three-fold, while spironolactone, a completive antagonist of aldosterone, completely abolished this LDL effect. Since MR is a known mineralocorticoid-responsive gene as well as an intracellular receptor molecule for this steroid, these results suggest that locally produced aldosterone is biologically active, stimulating the transcription rates of the mineralocorticoid-responsive genes by activating the MR in mesangial cells. These pieces of evidence indicate that human mesangial cells are an aldosterone-producing tissue in which LDL plays a major regulatory role. Therefore, human renal mesangial endocrine system may contribute to local aldosterone concentrations and effects in the renal glomerulus independently of the systemic renin--angiotensin--aldosterone system and may participate in the development and progression of glomerular damage in several pathologic conditions.
Nishikawa
Tetsuo
T
Department of Medicine, Yokohama Rosai Hospital, 3211 Kozukue-cho, Kohoku-ku, Yokohama City, Kanagawa 222-0036, Japan. tetsuon@yokohamah.rofuku.go.jp
Suematsu
Sachiko
S
Saito
Jun
J
Soyama
Akiko
A
Ito
Hiroko
H
Kino
Tomoshige
T
Chrousos
George
G
D015096:3-Hydroxysteroid Dehydrogenases / Q000235:genetics; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000450:Aldosterone / Q000032:analysis / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002786:Cholesterol Side-Chain Cleavage Enzyme / Q000235:genetics; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics; D005920:Glomerular Mesangium / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D011284:Pregnenolone / Q000032:analysis / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D011973:Receptors, LDL / Q000235:genetics*; D018161:Receptors, Mineralocorticoid / Q000235:genetics; D013255:Steroid 21-Hydroxylase / Q000235:genetics
D008077:Lipoproteins, LDL; D012333:RNA, Messenger; D011973:Receptors, LDL; D018161:Receptors, Mineralocorticoid; D000804:Angiotensin II; D000450:Aldosterone; D003994:Bucladesine; D011284:Pregnenolone; D000324:Adrenocorticotropic Hormone; D015096:3-Hydroxysteroid Dehydrogenases; D013255:Steroid 21-Hydroxylase; D019405:Cytochrome P-450 CYP11B2; D002786:Cholesterol Side-Chain Cleavage Enzyme